{"groups":[{"description":"All patients who received at least one dose of pralatrexate. Patients continued pralatrexate until protocol defined criteria for discontinuation or 24 months of treatment.","id":"FG000","title":"Full Population"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Treatment with pralatrexate ongoing"}],"milestones":[{"achievements":[{"comment":"Received at least one dose of pralatrexate.","groupId":"FG000","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"comment":"Treatment duration not limited. After treatment ends, patients attend survival follow-up visits.","groupId":"FG000","numSubjects":"107"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Treatment With Pralatrexate"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"24"}],"type":"Pts still in follow-up at data cutoff"}],"milestones":[{"achievements":[{"comment":"Patients (pts) who stop treatment with pralatrexate are followed for survival","groupId":"FG000","numSubjects":"107"}],"type":"STARTED"},{"achievements":[{"comment":"Pts who completed follow-up either died, were followed for 24 months, or withdrew","groupId":"FG000","numSubjects":"83"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Survival Follow-up, After Pralatrexate"}],"preAssignmentDetails":"Patients (pts) were required to have at least 10 days of vitamin supplementation during the up to 12 days between enrollment \\& dosing. Four of the 115 pts enrolled were excluded during this period: 2 did not have an eligible PTCL subtype per central review, 1 had the presence of B-cell lymphoma per the investigator, 1 had progressive disease.","recruitmentDetails":"Patients were enrolled between 24 August 2006 and 14 April 2008 across 25 study sites, 15 sites in the United States (US), 8 in Europe, and 2 in Canada."}